Jun 16, 2022 Checkpoint Therapeutics Announces Positive Interim Results from Registration-Enabling Trial of Cosibelimab in Locally Advanced Cutaneous Squamous Cell Carcinoma
Jun 06, 2022 Checkpoint Therapeutics Announces Presentation of Pivotal Trial Results of Cosibelimab at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
May 19, 2022 Checkpoint Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
May 13, 2022 Checkpoint Therapeutics Receives Pediatric Investigational Plan Waivers for Cosibelimab from the European Medicines Agency and U.K. Medicines & Healthcare Products Regulatory Agency
May 12, 2022 Checkpoint Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Highlights
Apr 28, 2022 Checkpoint Therapeutics Announces Data Presentation of Pivotal Trial Results of Cosibelimab to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Apr 04, 2022 Checkpoint Therapeutics to Present at the Virtual Fortress Biotech R&D Summit Hosted by B. Riley Securities
Mar 28, 2022 Checkpoint Therapeutics Reports Full-Year 2021 Financial Results and Recent Corporate Highlights
Jan 25, 2022 Checkpoint Therapeutics to Participate in the B. Riley Securities’ Virtual Oncology Conference
Jan 25, 2022 Checkpoint Therapeutics Announces Positive Topline Results from the Registration-Enabling Trial of Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma